

Agenda

7:30am	Continental Breakfast
8:00	Welcome Suephy C. Chen, MD, MS Professor and Chair of Duke Dermatology
8:10	Cutaneous toxicities of immune checkpoint inhibitors Sabrina Shearer, MD Duke Dermatology
8:30	Shared mechanisms of Anti-PD1 efficacy in tumor, and toxicity in tissue Niroshana Anandasabapathy, MD, PhD Weill Cornell Medicine
9:20	Melanoma in Veterans: clinical characteristics, genetics, and real-world effectiveness of immunotherapy Michelle Pavlis, MD Duke Dermatology
9:40	Break
9:55	Dermatology in the era of Immunotherapy: from skin toxicities to melanoma prognostication Eugene Semenov, MD, MA Massachusetts General, Harvard Medical School
10:50	Deciphering the etiology of skin malignancies through large-scale epidemiologic and multi-omic profiling Michael Sargen, MD National Cancer Institute, National Institutes of Health
11:40	The challenges of clinical margin assessment Matthew Draelos, MD, PhD Duke Dermatology
11:55	Lunch
1:00	Anti-leprosy drug clofazimine: an inhibitor of AhR signaling and a potent immunomodulator Mikhail Nikiforov, PhD Duke University
1:50	Targeting PCSK9 to overcome the resistance of LKB1-deficient lung cancer to immune checkpoint blockade immunotherapy Meng Jiao, PhD Duke University

- 2:05 **Targeting regulatory T-cells to enhance immunity against melanoma**
Wanying Miao, MD, PhD
Duke University
- 2:20 **Role of Inflammation and Stress in Melanoma Immune Evasion, Relapse, and Immunotherapy Resistance**
Brent Hanks, MD, PhD
Duke University
- 3:10 **Closing Remarks**
- 3:15-5:00 **Poster Session**